ONESOURCE · Healthcare · Biotechnology
Composite scorecard: 51/100 — Quality 49 · Momentum 56
| Share price | ₹1,693.90 |
| Market cap | ₹15,499 Cr |
| P/B ratio | 2.6 |
| ROE | 1.0% |
| ROCE | 1.4% |
| Book value | ₹518.08 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,422 Cr | ₹-74 Cr | 21.0% |
| 2025 | ₹1,445 Cr | ₹-18 Cr | 32.0% |
| 2024 | ₹172 Cr | ₹-391 Cr | -48.0% |
| 2023 | ₹39 Cr | ₹-800 Cr | -415.0% |
| 2022 | ₹132 Cr | ₹-231 Cr | -73.0% |
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoin